FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
10.94
+0.11 (1.02%)
At close: Oct 27, 2025, 4:00 PM EDT
11.12
+0.18 (1.65%)
After-hours: Oct 27, 2025, 4:10 PM EDT
FibroGen Revenue
FibroGen had revenue of $1.35M in the quarter ending June 30, 2025, with 35.07% growth. This brings the company's revenue in the last twelve months to $7.35M, down -200.44% year-over-year. In the year 2024, FibroGen had annual revenue of $29.62M, down -36.71%.
Revenue (ttm)
$7.35M
Revenue Growth
-200.44%
P/S Ratio
6.11
Revenue / Employee
$32,649
Employees
225
Market Cap
44.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
FGEN News
- 4 weeks ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 2 months ago - FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - GlobeNewsWire
- 2 months ago - FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - FibroGen to Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 4 months ago - FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewsWire